Medimmune Drug Patent Portfolio
Medimmune owns 1 orange book drug protected by 1 US patent Given below is the list of Medimmune's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6017922 | Thermally stable trimetrexates and processes for producing the same | 18 May, 2018 | Expired |
Medimmune's Family Patents
Clinical Trials
Recent Clinical Trials by Medimmune:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | MedImmune LLC | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | MedImmune LLC | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma | MedImmune LLC | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE2 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | MedImmune LLC | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |
Medimmune Drug List
Given below is the complete list of Medimmune's drugs and the patents protecting them.
1. Neutrexin
Neutrexin is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6017922 | Thermally stable trimetrexates and processes for producing the same |
18 May, 2018
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neutrexin's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List